The Medical Letter on Drugs and Therapeutics
Carbidopa/Levodopa Extended-Release Capsules (Rytary)
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.

The FDA has approved a new formulation of carbidopa/levodopa (Rytary – Impax) in extended-release capsules for treatment of Parkinson's disease (PD).

CARBIDOPA/LEVODOPA — The combination of levodopa and carbidopa is still the most effective pharmacologic treatment for symptomatic relief of PD.1 It has been available for many years as immediate- and sustained-release tablets (Sinemet, Sinemet CR, and generics), orally disintegrating tablets, and in combination with the COMT inhibitor entacapone (Stalevo, and generics). Sustained-release tablets have a slower and less predictable onset of action than immediate-release tablets. Many patients must take a half or a whole immediate-release tablet concomitantly with sustained-release tablets, particularly with the first dose of the day. Some small studies in patients with PD fluctuations have found ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App for iOS, Android, and Kindle Fire
  • FREE online per issue CME/CE
Purchase this article:
Title: Carbidopa Levodopa Extended-Release Capsules (Rytary)
Article code: 1467a
 Electronic, downloadable article - $45
Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.
Recommend to your librarian